Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.50
-3.2%
$4.38
$2.34
▼
$6.60
$554.35M0.962.25 million shs996,039 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.40
+0.1%
$51.78
$39.83
▼
$63.45
$3.93B1.921.73 million shs613,964 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.37
-6.1%
$0.56
$0.16
▼
$2.54
$90.56M0.7511.18 million shs2.25 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-7.91%-14.86%+10.06%-42.70%+43.25%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.43%-19.32%-18.03%-23.79%-23.15%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-4.12%-13.78%-18.89%-43.43%-74.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.50
-3.2%
$4.38
$2.34
▼
$6.60
$554.35M0.962.25 million shs996,039 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.40
+0.1%
$51.78
$39.83
▼
$63.45
$3.93B1.921.73 million shs613,964 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.37
-6.1%
$0.56
$0.16
▼
$2.54
$90.56M0.7511.18 million shs2.25 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-7.91%-14.86%+10.06%-42.70%+43.25%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.43%-19.32%-18.03%-23.79%-23.15%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-4.12%-13.78%-18.89%-43.43%-74.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.00
Buy$10.67205.20% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.65
Moderate Buy$72.9380.53% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.20
Hold$5.201,297.85% Upside

Current Analyst Ratings Breakdown

Latest ACRS, CRSP, and OTLK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Lower Price TargetBuy$13.00 ➝ $12.00
11/17/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
DowngradeOutperform ➝ Neutral$8.00 ➝ $3.00
11/10/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Reiterated RatingSell (D-)
11/10/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingOverweight$110.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Lower Price TargetEqual Weight$75.00 ➝ $70.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetBuy$88.00 ➝ $90.00
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingMarket Outperform
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingBuy$82.00
10/30/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Boost Price TargetBuy$10.00 ➝ $13.00
10/28/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Set Price Target$9.00
10/28/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Lower Price TargetOutperform$10.00 ➝ $8.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$6.40M86.60N/AN/A$1.05 per share3.33
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,116.41N/AN/A$16.99 per share2.38
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.35M67.08N/AN/A($0.60) per share-0.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$64.92M-$0.58N/AN/AN/A-1,244.09%-59.19%-42.19%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.74N/AN/AN/A-1,812.07%-25.59%-17.89%N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$0.77N/AN/AN/AN/AN/A-254.82%12/18/2026 (Estimated)

Latest ACRS, CRSP, and OTLK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.16-$0.12+$0.04-$0.12$1.27 million$1.48 million
11/2/2026Q3 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.06-$1.15-$0.09-$1.15$14.75 million$12.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.09
5.09
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.36
16.21
16.21
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.81
0.63

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
4.80%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
73158.61 million151.00 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39397.00 million91.96 millionOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
17243.45 million239.07 millionOptionable

Recent News About These Companies

Analyzing Entrada Therapeutics (NASDAQ:TRDA) & Oncobiologics (NASDAQ:OTLK)
Analyzing Oncobiologics (OTLK) & Its Peers

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$3.50 -0.12 (-3.19%)
As of 11:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$40.40 +0.03 (+0.07%)
As of 11:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.37 -0.02 (-6.06%)
As of 11:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.